nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—skin cancer—peripheral nervous system neoplasm	0.713	1	CtDrD
Imiquimod—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0328	0.265	CbGbCtD
Imiquimod—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0263	0.212	CbGbCtD
Imiquimod—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0172	0.139	CbGbCtD
Imiquimod—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.016	0.129	CbGbCtD
Imiquimod—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0128	0.104	CbGbCtD
Imiquimod—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00735	0.0593	CbGbCtD
Imiquimod—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00673	0.0544	CbGbCtD
Imiquimod—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00459	0.0371	CbGbCtD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—IFNB1—peripheral nervous system neoplasm	7.91e-05	0.0662	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—IFNB1—peripheral nervous system neoplasm	6.18e-05	0.0517	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—IFNB1—peripheral nervous system neoplasm	6e-05	0.0502	CbGpPWpGaD
Imiquimod—Breast disorder—Epirubicin—peripheral nervous system neoplasm	5.67e-05	0.00035	CcSEcCtD
Imiquimod—Face oedema—Doxorubicin—peripheral nervous system neoplasm	5.61e-05	0.000346	CcSEcCtD
Imiquimod—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	5.6e-05	0.000346	CcSEcCtD
Imiquimod—Urticaria—Alitretinoin—peripheral nervous system neoplasm	5.6e-05	0.000346	CcSEcCtD
Imiquimod—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	5.57e-05	0.000344	CcSEcCtD
Imiquimod—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	5.57e-05	0.000344	CcSEcCtD
Imiquimod—Nausea—Topotecan—peripheral nervous system neoplasm	5.57e-05	0.000344	CcSEcCtD
Imiquimod—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	5.55e-05	0.000343	CcSEcCtD
Imiquimod—Nausea—Tretinoin—peripheral nervous system neoplasm	5.52e-05	0.000341	CcSEcCtD
Imiquimod—Nausea—Isotretinoin—peripheral nervous system neoplasm	5.52e-05	0.000341	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	5.47e-05	0.000338	CcSEcCtD
Imiquimod—Infection—Etoposide—peripheral nervous system neoplasm	5.47e-05	0.000338	CcSEcCtD
Imiquimod—Asthenia—Dactinomycin—peripheral nervous system neoplasm	5.45e-05	0.000337	CcSEcCtD
Imiquimod—Nausea—Melphalan—peripheral nervous system neoplasm	5.45e-05	0.000337	CcSEcCtD
Imiquimod—Influenza—Epirubicin—peripheral nervous system neoplasm	5.42e-05	0.000335	CcSEcCtD
Imiquimod—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	5.39e-05	0.000333	CcSEcCtD
Imiquimod—Tachycardia—Etoposide—peripheral nervous system neoplasm	5.37e-05	0.000332	CcSEcCtD
Imiquimod—Abdominal pain—Vincristine—peripheral nervous system neoplasm	5.37e-05	0.000332	CcSEcCtD
Imiquimod—Body temperature increased—Vincristine—peripheral nervous system neoplasm	5.37e-05	0.000332	CcSEcCtD
Imiquimod—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	5.35e-05	0.000331	CcSEcCtD
Imiquimod—Skin disorder—Etoposide—peripheral nervous system neoplasm	5.34e-05	0.00033	CcSEcCtD
Imiquimod—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	5.32e-05	0.000328	CcSEcCtD
Imiquimod—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	5.25e-05	0.000324	CcSEcCtD
Imiquimod—Anorexia—Etoposide—peripheral nervous system neoplasm	5.25e-05	0.000324	CcSEcCtD
Imiquimod—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	5.22e-05	0.000322	CcSEcCtD
Imiquimod—Bronchitis—Epirubicin—peripheral nervous system neoplasm	5.22e-05	0.000322	CcSEcCtD
Imiquimod—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	5.2e-05	0.000321	CcSEcCtD
Imiquimod—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	5.19e-05	0.000321	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	5.19e-05	0.00032	CcSEcCtD
Imiquimod—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	5.15e-05	0.000318	CcSEcCtD
Imiquimod—Pain—Cisplatin—peripheral nervous system neoplasm	5.14e-05	0.000317	CcSEcCtD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—PTPN11—peripheral nervous system neoplasm	5.11e-05	0.0428	CbGpPWpGaD
Imiquimod—Dysuria—Epirubicin—peripheral nervous system neoplasm	5.07e-05	0.000313	CcSEcCtD
Imiquimod—Asthenia—Alitretinoin—peripheral nervous system neoplasm	5.06e-05	0.000312	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	5.04e-05	0.000311	CcSEcCtD
Imiquimod—Influenza—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.00031	CcSEcCtD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—PTPN11—peripheral nervous system neoplasm	5.02e-05	0.042	CbGpPWpGaD
Imiquimod—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	5e-05	0.000309	CcSEcCtD
Imiquimod—Pruritus—Alitretinoin—peripheral nervous system neoplasm	4.99e-05	0.000308	CcSEcCtD
Imiquimod—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	4.95e-05	0.000306	CcSEcCtD
Imiquimod—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	4.95e-05	0.000306	CcSEcCtD
Imiquimod—Paraesthesia—Etoposide—peripheral nervous system neoplasm	4.94e-05	0.000305	CcSEcCtD
Imiquimod—Dyspnoea—Etoposide—peripheral nervous system neoplasm	4.91e-05	0.000303	CcSEcCtD
Imiquimod—Somnolence—Etoposide—peripheral nervous system neoplasm	4.89e-05	0.000302	CcSEcCtD
Imiquimod—Asthenia—Vincristine—peripheral nervous system neoplasm	4.87e-05	0.000301	CcSEcCtD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—PTPN11—peripheral nervous system neoplasm	4.84e-05	0.0405	CbGpPWpGaD
Imiquimod—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	4.84e-05	0.000299	CcSEcCtD
Imiquimod—Infestation—Epirubicin—peripheral nervous system neoplasm	4.84e-05	0.000299	CcSEcCtD
Imiquimod—Vomiting—Dactinomycin—peripheral nervous system neoplasm	4.83e-05	0.000298	CcSEcCtD
Imiquimod—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	4.83e-05	0.000298	CcSEcCtD
Imiquimod—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	4.82e-05	0.000298	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000296	CcSEcCtD
Imiquimod—Rash—Dactinomycin—peripheral nervous system neoplasm	4.79e-05	0.000296	CcSEcCtD
Imiquimod—Decreased appetite—Etoposide—peripheral nervous system neoplasm	4.78e-05	0.000295	CcSEcCtD
Imiquimod—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	4.77e-05	0.000294	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	4.75e-05	0.000293	CcSEcCtD
Imiquimod—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	4.75e-05	0.000293	CcSEcCtD
Imiquimod—Fatigue—Etoposide—peripheral nervous system neoplasm	4.74e-05	0.000293	CcSEcCtD
Imiquimod—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	4.74e-05	0.000293	CcSEcCtD
Imiquimod—Pain—Etoposide—peripheral nervous system neoplasm	4.71e-05	0.000291	CcSEcCtD
Imiquimod—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	4.7e-05	0.00029	CcSEcCtD
Imiquimod—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	4.7e-05	0.00029	CcSEcCtD
Imiquimod—Dysuria—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.00029	CcSEcCtD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—IFNB1—peripheral nervous system neoplasm	4.68e-05	0.0392	CbGpPWpGaD
Imiquimod—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.000288	CcSEcCtD
Imiquimod—Dizziness—Alitretinoin—peripheral nervous system neoplasm	4.66e-05	0.000288	CcSEcCtD
Imiquimod—Diarrhoea—Vincristine—peripheral nervous system neoplasm	4.65e-05	0.000287	CcSEcCtD
Imiquimod—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	4.58e-05	0.000283	CcSEcCtD
Imiquimod—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	4.57e-05	0.000282	CcSEcCtD
Imiquimod—Sinusitis—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.00028	CcSEcCtD
Imiquimod—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	4.53e-05	0.00028	CcSEcCtD
Imiquimod—Nausea—Dactinomycin—peripheral nervous system neoplasm	4.52e-05	0.000279	CcSEcCtD
Imiquimod—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	4.5e-05	0.000278	CcSEcCtD
Imiquimod—Dizziness—Vincristine—peripheral nervous system neoplasm	4.49e-05	0.000277	CcSEcCtD
Imiquimod—Vomiting—Alitretinoin—peripheral nervous system neoplasm	4.48e-05	0.000277	CcSEcCtD
Imiquimod—Infestation—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000276	CcSEcCtD
Imiquimod—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000276	CcSEcCtD
Imiquimod—Rash—Alitretinoin—peripheral nervous system neoplasm	4.44e-05	0.000274	CcSEcCtD
Imiquimod—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	4.44e-05	0.000274	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000274	CcSEcCtD
Imiquimod—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	4.43e-05	0.000273	CcSEcCtD
Imiquimod—Headache—Alitretinoin—peripheral nervous system neoplasm	4.42e-05	0.000273	CcSEcCtD
Imiquimod—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	4.39e-05	0.000271	CcSEcCtD
Imiquimod—Urticaria—Etoposide—peripheral nervous system neoplasm	4.37e-05	0.00027	CcSEcCtD
Imiquimod—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	4.36e-05	0.000269	CcSEcCtD
Imiquimod—Rhinitis—Epirubicin—peripheral nervous system neoplasm	4.35e-05	0.000269	CcSEcCtD
Imiquimod—Body temperature increased—Etoposide—peripheral nervous system neoplasm	4.35e-05	0.000269	CcSEcCtD
Imiquimod—Abdominal pain—Etoposide—peripheral nervous system neoplasm	4.35e-05	0.000269	CcSEcCtD
Imiquimod—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000269	CcSEcCtD
Imiquimod—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000269	CcSEcCtD
Imiquimod—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000268	CcSEcCtD
Imiquimod—Vomiting—Vincristine—peripheral nervous system neoplasm	4.32e-05	0.000267	CcSEcCtD
Imiquimod—Asthenia—Cisplatin—peripheral nervous system neoplasm	4.31e-05	0.000266	CcSEcCtD
Imiquimod—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000266	CcSEcCtD
Imiquimod—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.000265	CcSEcCtD
Imiquimod—Rash—Vincristine—peripheral nervous system neoplasm	4.28e-05	0.000264	CcSEcCtD
Imiquimod—Dermatitis—Vincristine—peripheral nervous system neoplasm	4.28e-05	0.000264	CcSEcCtD
Imiquimod—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	4.27e-05	0.000263	CcSEcCtD
Imiquimod—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	4.26e-05	0.000263	CcSEcCtD
Imiquimod—Headache—Vincristine—peripheral nervous system neoplasm	4.26e-05	0.000263	CcSEcCtD
Imiquimod—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	4.23e-05	0.000261	CcSEcCtD
Imiquimod—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000259	CcSEcCtD
Imiquimod—Nausea—Alitretinoin—peripheral nervous system neoplasm	4.19e-05	0.000259	CcSEcCtD
Imiquimod—Visual impairment—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.000258	CcSEcCtD
Imiquimod—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	4.11e-05	0.000254	CcSEcCtD
Imiquimod—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	4.1e-05	0.000253	CcSEcCtD
Imiquimod—Eye disorder—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000251	CcSEcCtD
Imiquimod—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	4.05e-05	0.00025	CcSEcCtD
Imiquimod—Tinnitus—Epirubicin—peripheral nervous system neoplasm	4.05e-05	0.00025	CcSEcCtD
Imiquimod—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	4.04e-05	0.000249	CcSEcCtD
Imiquimod—Nausea—Vincristine—peripheral nervous system neoplasm	4.03e-05	0.000249	CcSEcCtD
Imiquimod—Flushing—Epirubicin—peripheral nervous system neoplasm	4.03e-05	0.000249	CcSEcCtD
Imiquimod—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	4.03e-05	0.000249	CcSEcCtD
Imiquimod—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.000248	CcSEcCtD
Imiquimod—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000246	CcSEcCtD
Imiquimod—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.000245	CcSEcCtD
Imiquimod—Asthenia—Etoposide—peripheral nervous system neoplasm	3.95e-05	0.000244	CcSEcCtD
Imiquimod—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	3.95e-05	0.000244	CcSEcCtD
Imiquimod—Angiopathy—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000243	CcSEcCtD
Imiquimod—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	3.94e-05	0.000243	CcSEcCtD
Imiquimod—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	3.92e-05	0.000242	CcSEcCtD
Imiquimod—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000242	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—CD55—peripheral nervous system neoplasm	3.91e-05	0.0327	CbGpPWpGaD
Imiquimod—Chills—Epirubicin—peripheral nervous system neoplasm	3.9e-05	0.000241	CcSEcCtD
Imiquimod—Pruritus—Etoposide—peripheral nervous system neoplasm	3.89e-05	0.00024	CcSEcCtD
Imiquimod—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000239	CcSEcCtD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—PTPN11—peripheral nervous system neoplasm	3.87e-05	0.0324	CbGpPWpGaD
Imiquimod—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000239	CcSEcCtD
Imiquimod—Alopecia—Epirubicin—peripheral nervous system neoplasm	3.84e-05	0.000237	CcSEcCtD
Imiquimod—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.82e-05	0.000236	CcSEcCtD
Imiquimod—Mental disorder—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.000235	CcSEcCtD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—PTPN11—peripheral nervous system neoplasm	3.8e-05	0.0318	CbGpPWpGaD
Imiquimod—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	0.000235	CcSEcCtD
Imiquimod—Rash—Cisplatin—peripheral nervous system neoplasm	3.79e-05	0.000234	CcSEcCtD
Imiquimod—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.78e-05	0.000234	CcSEcCtD
Imiquimod—Malnutrition—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.000233	CcSEcCtD
Imiquimod—Erythema—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.000233	CcSEcCtD
Imiquimod—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.76e-05	0.000232	CcSEcCtD
Imiquimod—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000232	CcSEcCtD
Imiquimod—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000231	CcSEcCtD
Imiquimod—Flushing—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.00023	CcSEcCtD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—PTPN11—peripheral nervous system neoplasm	3.67e-05	0.0307	CbGpPWpGaD
Imiquimod—Back pain—Epirubicin—peripheral nervous system neoplasm	3.66e-05	0.000226	CcSEcCtD
Imiquimod—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.000225	CcSEcCtD
Imiquimod—Dizziness—Etoposide—peripheral nervous system neoplasm	3.64e-05	0.000225	CcSEcCtD
Imiquimod—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	3.63e-05	0.000224	CcSEcCtD
Imiquimod—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000224	CcSEcCtD
Imiquimod—Chills—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000223	CcSEcCtD
Imiquimod—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000222	CcSEcCtD
Imiquimod—Nausea—Cisplatin—peripheral nervous system neoplasm	3.57e-05	0.00022	CcSEcCtD
Imiquimod—Alopecia—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000219	CcSEcCtD
Imiquimod—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000217	CcSEcCtD
Imiquimod—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.000217	CcSEcCtD
Imiquimod—Vomiting—Etoposide—peripheral nervous system neoplasm	3.5e-05	0.000216	CcSEcCtD
Imiquimod—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	3.5e-05	0.000216	CcSEcCtD
Imiquimod—Erythema—Doxorubicin—peripheral nervous system neoplasm	3.5e-05	0.000216	CcSEcCtD
Imiquimod—Agitation—Epirubicin—peripheral nervous system neoplasm	3.47e-05	0.000214	CcSEcCtD
Imiquimod—Rash—Etoposide—peripheral nervous system neoplasm	3.47e-05	0.000214	CcSEcCtD
Imiquimod—Dermatitis—Etoposide—peripheral nervous system neoplasm	3.47e-05	0.000214	CcSEcCtD
Imiquimod—Headache—Etoposide—peripheral nervous system neoplasm	3.45e-05	0.000213	CcSEcCtD
Imiquimod—TLR8—Toll-Like Receptors Cascades—PTPN11—peripheral nervous system neoplasm	3.44e-05	0.0288	CbGpPWpGaD
Imiquimod—Malaise—Epirubicin—peripheral nervous system neoplasm	3.41e-05	0.00021	CcSEcCtD
Imiquimod—Syncope—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000209	CcSEcCtD
Imiquimod—Back pain—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000209	CcSEcCtD
Imiquimod—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.34e-05	0.000206	CcSEcCtD
Imiquimod—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.32e-05	0.000205	CcSEcCtD
Imiquimod—Cough—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.000204	CcSEcCtD
Imiquimod—Convulsion—Epirubicin—peripheral nervous system neoplasm	3.27e-05	0.000202	CcSEcCtD
Imiquimod—Nausea—Etoposide—peripheral nervous system neoplasm	3.27e-05	0.000202	CcSEcCtD
Imiquimod—Hypertension—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000201	CcSEcCtD
Imiquimod—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.0002	CcSEcCtD
Imiquimod—Myalgia—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000199	CcSEcCtD
Imiquimod—Chest pain—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000199	CcSEcCtD
Imiquimod—Arthralgia—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000199	CcSEcCtD
Imiquimod—Agitation—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000198	CcSEcCtD
Imiquimod—Anxiety—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000198	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	3.2e-05	0.000197	CcSEcCtD
Imiquimod—Discomfort—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000196	CcSEcCtD
Imiquimod—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.15e-05	0.000195	CcSEcCtD
Imiquimod—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.15e-05	0.000194	CcSEcCtD
Imiquimod—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000194	CcSEcCtD
Imiquimod—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.09e-05	0.000191	CcSEcCtD
Imiquimod—Oedema—Epirubicin—peripheral nervous system neoplasm	3.08e-05	0.00019	CcSEcCtD
Imiquimod—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.07e-05	0.00019	CcSEcCtD
Imiquimod—Infection—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.000189	CcSEcCtD
Imiquimod—Cough—Doxorubicin—peripheral nervous system neoplasm	3.05e-05	0.000188	CcSEcCtD
Imiquimod—Shock—Epirubicin—peripheral nervous system neoplasm	3.03e-05	0.000187	CcSEcCtD
Imiquimod—Convulsion—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	0.000187	CcSEcCtD
Imiquimod—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.02e-05	0.000187	CcSEcCtD
Imiquimod—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.000186	CcSEcCtD
Imiquimod—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.000186	CcSEcCtD
Imiquimod—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000185	CcSEcCtD
Imiquimod—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.98e-05	0.000184	CcSEcCtD
Imiquimod—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000184	CcSEcCtD
Imiquimod—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000184	CcSEcCtD
Imiquimod—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000184	CcSEcCtD
Imiquimod—Anxiety—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000183	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—CD55—peripheral nervous system neoplasm	2.96e-05	0.0248	CbGpPWpGaD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	0.000183	CcSEcCtD
Imiquimod—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000182	CcSEcCtD
Imiquimod—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.94e-05	0.000182	CcSEcCtD
Imiquimod—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.91e-05	0.00018	CcSEcCtD
Imiquimod—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.85e-05	0.000176	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	2.85e-05	0.0239	CbGpPWpGaD
Imiquimod—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	2.84e-05	0.0238	CbGpPWpGaD
Imiquimod—Infection—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	0.000175	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.81e-05	0.000174	CcSEcCtD
Imiquimod—Shock—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	0.000173	CcSEcCtD
Imiquimod—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.8e-05	0.000173	CcSEcCtD
Imiquimod—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.79e-05	0.000172	CcSEcCtD
Imiquimod—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000172	CcSEcCtD
Imiquimod—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	0.000171	CcSEcCtD
Imiquimod—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.77e-05	0.000171	CcSEcCtD
Imiquimod—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.00017	CcSEcCtD
Imiquimod—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.75e-05	0.00017	CcSEcCtD
Imiquimod—Somnolence—Epirubicin—peripheral nervous system neoplasm	2.74e-05	0.000169	CcSEcCtD
Imiquimod—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.72e-05	0.000168	CcSEcCtD
Imiquimod—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000168	CcSEcCtD
Imiquimod—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.68e-05	0.000166	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	2.66e-05	0.000164	CcSEcCtD
Imiquimod—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.66e-05	0.000164	CcSEcCtD
Imiquimod—Pain—Epirubicin—peripheral nervous system neoplasm	2.64e-05	0.000163	CcSEcCtD
Imiquimod—TLR7—Toll-Like Receptors Cascades—PTPN11—peripheral nervous system neoplasm	2.61e-05	0.0218	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	2.6e-05	0.000161	CcSEcCtD
Imiquimod—Insomnia—Doxorubicin—peripheral nervous system neoplasm	2.58e-05	0.000159	CcSEcCtD
Imiquimod—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	0.000158	CcSEcCtD
Imiquimod—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.54e-05	0.000157	CcSEcCtD
Imiquimod—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.54e-05	0.000157	CcSEcCtD
Imiquimod—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.54e-05	0.000157	CcSEcCtD
Imiquimod—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.52e-05	0.000156	CcSEcCtD
Imiquimod—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	0.000155	CcSEcCtD
Imiquimod—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.48e-05	0.000153	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	0.000152	CcSEcCtD
Imiquimod—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	0.000152	CcSEcCtD
Imiquimod—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.45e-05	0.000151	CcSEcCtD
Imiquimod—Pain—Doxorubicin—peripheral nervous system neoplasm	2.44e-05	0.000151	CcSEcCtD
Imiquimod—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.44e-05	0.000151	CcSEcCtD
Imiquimod—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.44e-05	0.000151	CcSEcCtD
Imiquimod—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	2.41e-05	0.0202	CbGpPWpGaD
Imiquimod—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.35e-05	0.000145	CcSEcCtD
Imiquimod—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	0.000144	CcSEcCtD
Imiquimod—TLR8—Immune System—CD55—peripheral nervous system neoplasm	2.28e-05	0.0191	CbGpPWpGaD
Imiquimod—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.27e-05	0.00014	CcSEcCtD
Imiquimod—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	0.00014	CcSEcCtD
Imiquimod—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.26e-05	0.000139	CcSEcCtD
Imiquimod—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.26e-05	0.000139	CcSEcCtD
Imiquimod—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.21e-05	0.000137	CcSEcCtD
Imiquimod—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.18e-05	0.000135	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	2.16e-05	0.0181	CbGpPWpGaD
Imiquimod—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.11e-05	0.00013	CcSEcCtD
Imiquimod—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.1e-05	0.00013	CcSEcCtD
Imiquimod—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.05e-05	0.000126	CcSEcCtD
Imiquimod—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.04e-05	0.000126	CcSEcCtD
Imiquimod—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.02e-05	0.000125	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—IFNB1—peripheral nervous system neoplasm	1.98e-05	0.0166	CbGpPWpGaD
Imiquimod—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.96e-05	0.000121	CcSEcCtD
Imiquimod—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.95e-05	0.000121	CcSEcCtD
Imiquimod—Rash—Epirubicin—peripheral nervous system neoplasm	1.94e-05	0.00012	CcSEcCtD
Imiquimod—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.94e-05	0.00012	CcSEcCtD
Imiquimod—Headache—Epirubicin—peripheral nervous system neoplasm	1.93e-05	0.000119	CcSEcCtD
Imiquimod—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.89e-05	0.000117	CcSEcCtD
Imiquimod—Nausea—Epirubicin—peripheral nervous system neoplasm	1.83e-05	0.000113	CcSEcCtD
Imiquimod—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.81e-05	0.000112	CcSEcCtD
Imiquimod—Rash—Doxorubicin—peripheral nervous system neoplasm	1.8e-05	0.000111	CcSEcCtD
Imiquimod—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.8e-05	0.000111	CcSEcCtD
Imiquimod—Headache—Doxorubicin—peripheral nervous system neoplasm	1.79e-05	0.00011	CcSEcCtD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.73e-05	0.0145	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD55—peripheral nervous system neoplasm	1.73e-05	0.0145	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD34—peripheral nervous system neoplasm	1.73e-05	0.0145	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	1.71e-05	0.0143	CbGpPWpGaD
Imiquimod—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.7e-05	0.000105	CcSEcCtD
Imiquimod—TLR8—Immune System—PPP3R1—peripheral nervous system neoplasm	1.66e-05	0.0139	CbGpPWpGaD
Imiquimod—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	1.55e-05	0.013	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IFNB1—peripheral nervous system neoplasm	1.5e-05	0.0126	CbGpPWpGaD
Imiquimod—TLR8—Immune System—NCAM1—peripheral nervous system neoplasm	1.47e-05	0.0123	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	1.35e-05	0.0113	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.31e-05	0.011	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD34—peripheral nervous system neoplasm	1.31e-05	0.011	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PPP3R1—peripheral nervous system neoplasm	1.26e-05	0.0105	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	1.16e-05	0.00969	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IFNB1—peripheral nervous system neoplasm	1.15e-05	0.00965	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.11e-05	0.00933	CbGpPWpGaD
Imiquimod—TLR7—Immune System—NCAM1—peripheral nervous system neoplasm	1.11e-05	0.00932	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	1.02e-05	0.00857	CbGpPWpGaD
Imiquimod—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	9.37e-06	0.00785	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	8.93e-06	0.00748	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HGF—peripheral nervous system neoplasm	8.9e-06	0.00745	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—ERBB2—peripheral nervous system neoplasm	8.81e-06	0.00737	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IFNB1—peripheral nervous system neoplasm	8.73e-06	0.00731	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PTPN11—peripheral nervous system neoplasm	8.44e-06	0.00707	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HGF—peripheral nervous system neoplasm	6.74e-06	0.00564	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—NRAS—peripheral nervous system neoplasm	6.7e-06	0.00561	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—ERBB2—peripheral nervous system neoplasm	6.67e-06	0.00559	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PTPN11—peripheral nervous system neoplasm	6.49e-06	0.00543	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ERBB2—peripheral nervous system neoplasm	5.13e-06	0.00429	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—NRAS—peripheral nervous system neoplasm	5.08e-06	0.00425	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PTPN11—peripheral nervous system neoplasm	4.92e-06	0.00412	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.9e-06	0.0041	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	4.36e-06	0.00365	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.33e-06	0.00362	CbGpPWpGaD
Imiquimod—TLR8—Immune System—NRAS—peripheral nervous system neoplasm	3.9e-06	0.00327	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ERBB2—peripheral nervous system neoplasm	3.89e-06	0.00325	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	3.87e-06	0.00324	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.71e-06	0.00311	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	3.6e-06	0.00302	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.28e-06	0.00275	CbGpPWpGaD
Imiquimod—TLR7—Immune System—NRAS—peripheral nervous system neoplasm	2.96e-06	0.00248	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.87e-06	0.0024	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HRAS—peripheral nervous system neoplasm	2.85e-06	0.00239	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	2.83e-06	0.00237	CbGpPWpGaD
Imiquimod—TLR8—Immune System—AKT1—peripheral nervous system neoplasm	2.52e-06	0.00211	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.22e-06	0.00186	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HRAS—peripheral nervous system neoplasm	2.16e-06	0.00181	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.94e-06	0.00162	CbGpPWpGaD
Imiquimod—TLR7—Immune System—AKT1—peripheral nervous system neoplasm	1.91e-06	0.0016	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.61e-06	0.00135	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.5e-06	0.00125	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.4e-06	0.00117	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.34e-06	0.00113	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.29e-06	0.00108	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.08e-06	0.000906	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.04e-06	0.000869	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	9.99e-07	0.000836	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	8.5e-07	0.000712	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	7.18e-07	0.000601	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.85e-07	0.000574	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	6.75e-07	0.000565	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	6.56e-07	0.000549	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	5.54e-07	0.000464	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	5.51e-07	0.000461	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	5.41e-07	0.000453	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.29e-07	0.000443	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	5.21e-07	0.000436	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	4.25e-07	0.000356	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.17e-07	0.000349	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.49e-07	0.000125	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.15e-07	9.61e-05	CbGpPWpGaD
